PHOSPHODESTERASE TYPE 5 INHIBITORS - CLINICAL EFFICIENCY AND ROLE IN THERAPY FOR ERECTILE DYSFUNCTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article discusses the physiological mechanisms of erection and the pathophysiological basis oferectile dysfunction. Parameters characterizing the features of the pharmacokinetics and pharmacodynamics of drugs from the group of phosphodiesterase type 5 inhibitors (PDE-5i) are presented. The clinical efficacy and possible adverse effects of the most significant PDE-5i are considered. These include sildenafil, tadalafil, vardenafil, udenafil, avanafil. There are also data on less known PDE-5i, which include lodenafil and mirodenafil.

Full Text

Restricted Access

About the authors

Z. R Shodmonova

Samarkand State Medical Institute

Email: zebuniso.shodmonova@mail.ru
PhD, associate professor Head of the Department of Urology Samarkand, Uzbekistan

R. R Gafarov

Samarkand State Medical Institute

Email: rushen.gafarov@bk.ru
assistant at the Department of Urology Samarkand, Uzbekistan

S. A Allazov

Samarkand State Medical Institute

Email: salah.allazovich@mail.ru
professor at the Department of Urology Samarkand, Uzbekistan

Sh. I Giyasov

Tashkent Medical Academy

Email: dr.sh.giyasov@gmail.com
MD, associate professor at the Department of Urology, Consultant at Republican Specialized Scientific and Practical Medical Center of Urology Tashkent, Uzbekistan

References

  1. Wylie K. Erectile dysfunction. Adv Psychosom Med. 2008;29:33-49. doi: 10.1159/000126623.
  2. Чалый М.Е., Ахвледиани Н.Д., Харчилава Р.Р. Эректильная дисфункция. Российские клинические рекомендации. Урология. 2017; 2 (Приложение 2): 20-30.
  3. Dean R.C., Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379-395, v. doi: 10.1016/j.ucl.2005.08.007.
  4. Cho M.C., Paick J.S. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341-354. doi: 10.2147/TCRM.S39727.
  5. Pastuszak A.W. Current Diagnosis and Management of Erectile Dysfunction. Curr Sex Health Rep. 2014;6(3): 164-176. Doi: 10.1007/ s11930-014-0023-9.
  6. Lue T.F. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813. doi: 10.1056/NEJM200006153422407.
  7. McVary K.T. Erectile dysfunction. New Engl. J. Med. 2007;357:2472-2481. doi: 10.1056/NEJMcp067261.
  8. Yafi F.A., Jenkins L., Albersen M., Corona G., Isidori A.M., Goldfarb S., Maggi M., Nelson C.J., Parish S., Salonia A., Tan R, Mulhall J.P., Hellstrom W.J. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003. doi: 10.1038/nrdp.2016.3.
  9. Perelman M.A. The impact of relationship variables on the etiology, diagnosis and treatment of erectile dysfunction. Adv Primary Care Med: Clin Updat. 2007;3:3-6.
  10. Porst H., Burnett A., Brock G., Ghanem H., Giuliano F., Glina S., et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130-171. doi: 10.1111/jsm.12023.
  11. Tsertsvadze A., Fink H.A., Yazdi F., MacDonald R., Bella A.J., Ansari M.T., et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and metaanalysis. Ann Intern Med. 2009;151(9):650-661. doi: 10.7326/0003-4819-151-9-200911030-00150.
  12. Tsertsvadze A., Yazdi F., Fink H.A., et al. Diagnosis and treatment of erectile dysfunction. Vol. 171. Agency for Healthcare Research and Quality (US); Rockville: 2009.
  13. JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-912. doi: 10.1016/j.eururo.2013.10.014.
  14. Дамулин И.В., Есилевский Ю.М. Эректильная дисфункция: современное состояние проблемы. Урология, 2014;3:95-101.
  15. Chen L., Staubli S.E., Schneider M.P., Kessels A.G., Ivic S., Bachmann L.M., Kessler T.M. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-offnetwork meta-analysis. Eur Urol. 2015;68(4):674- 680. doi: 10.1016/j.eururo.2015.03.031.
  16. Fink H.A., Mac Donald R., Rutks I.R. et al. Sildenafil for male erectile dysfunction. Arch. Intern. Med. 2002; 162: 1349-1360. Doi: 10.1001/ archinte.162.12.1349.
  17. Григорян В.А., Газимиев М.А., Демидко Ю.Л., Байдувалиев А.М. Лекарственные формы силденафила для лечения нарушений эрекции. Урология. 2018;1:159-162). Doi: https://dx.doi.org/10.18565/urology.2018.1.159-162.
  18. Damle B., Duczynski G., Jeffers B.W., et al. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014;36(2):236-244. doi: 10.1016/j.clinthera.2013.12.010.
  19. Локшин К.Л. Сравнительная характеристика силденафила и других ингибиторов фосфодиэстеразы 5-го типа в лечении больных эректильной дисфункцией (обзор литературы). Русский медицинский журнал. 2013;18:936-939.
  20. Гамидов С.И., Овчинников Р.И., Попова А.Ю., Ижбаев С.Х. Ингибиторы фосфодиэстеразы 5-го типа в лечении эректильной дисфункции: прошлое, настоящее и будущее. Урология. 2017;1:103-108. Doi: https://dx.doi.org/10.18565/urol.2017.1.103-107.
  21. Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Büttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9:1418-1429. doi: 10.1111/j.1743-6109.2012.02667.x.
  22. Gacci M., Corona G., Salvi M., Vignozzi L., McVary K.T., Kaplan S.A., et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alphablockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033.
  23. Porst H., McVary K.T., Montorsi F. et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur. Urol. 2009;56(4):727-735. doi: 10.1016/j.eururo.2009.04.033.
  24. Волков А.А., Петричко М.И., Будник Н.В. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа - коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014; 4:64-68.
  25. Crowe S.M., Streetman D.S. Vardenafil treatment for erectile dysfunction. Ann Pharmacother. 2004;38(1):77-85. doi: 10.1345/aph.1D019.
  26. Корнеев И.А. Левитра® (орально диспергируемая таблетка) - инновационный препарат для лечения больных эректильной дисфункцией. Урология 2013; 2:106-111.
  27. Sanford M. Vardenafil orodispersible tablet. Drugs. 2012;72(1):87-98. doi: 10.2165/11208270-000000000-00000.
  28. Hatzimuratidis et al. EAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism, 2019.
  29. Kang S.G., Kim J.J. Udenafil: efficacy and tolerability in the management of erectile dysfunction. Ther Adv Urol. 2013;5(2) : 101-110. doi: 10.1177/1756287212470019.
  30. Paick J.S., Kim S.W., Yang D.Y., et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med. 2008;5(4):946-953. doi: 10.1111/j.1743-6109.2007.00723.x.
  31. Kim B.H., Lim H.S., Chung J.Y., Kim J.R., Lim K.S., Sohn D.R., et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008;65(6):848-854. doi: 10.1111/j.1365-2125.2008.03107.x.
  32. Corona G., Rastrelli G., Burri A., Jannini E.A., Maggi M. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf 2016;15:237-247. doi: 10.1517/14740338.2016.1130126.
  33. Goldstein I., McCullough A.R., Jones L.A., Hellstrom W.J., Bowden C.H., Didonato K., et al. A randomized, double-blind, placebocontrolled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122-1133. Doi: 10.1111/j. 1743-6109.2011.02629.x.
  34. Kyle J.A., Brown D.A., Hill J.K. Avanafil for erectile dysfunction. The Annals of pharmacotherapy. 2013;47(10): 1312-1320. doi: 10.1177/1060028013501989.
  35. Glina S., Toscano I., Gomatzky C., de Goes P.M., Junior A.N., Claro J.F., Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009;6(2):553- 557. doi: 10.1111/j.1743-6109.2008.01079.x.
  36. Glina S., Fonseca G.N., Bertero E.B., et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7(5): 1928-1936. Doi: 10.1111/j. 1743-6109.2010.01711.x.
  37. Peak T.C., Yafi F.A., Sangkum P., Hellstrom W.J. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20(2):263-275. doi: 10.1517/14728214.2015.1021682.
  38. Park H.J., Moon K.H., Lee S.W., Lee W.K., Kam S.C., Lee J.H., Park N.C. Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. World J Mens Health. 2014;32(1):18-27. Doi: 10.5534/ wjmh.2014.32.1.18.
  39. Paick J.S., Ahn T.Y., Choi H.K., et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5( 11):2672-2680. Doi: 10.1111/j. 1743-6109.2008.00945.x.
  40. Lee J.Y., Cho S.Y., Oh C.Y., et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. Int J Impot Res 2011;23(6):249-256. doi: 10.1038/ijir.2011.34.
  41. Tashkenbaeva E., Nasirova Z., Ziyadullaev S., Kadirova F. The Role of Biopsychosocial Risk Factors on the Intensification of Unstable Angina. International Journal of Advanced Science and Technology. 2020;29(05):1948-1952.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies